France fights to prevent EU approval of obesity drug
This article was originally published in SRA
Executive Summary
France is pursuing its efforts to prevent the European Commission from approving Orexigen's weight loss combination product Mysimba (naltrexone/bupropion) on safety and efficacy grounds, and has taken the matter to the commission's Standing Committee on Medicinal Products for Human Use1,2.